Gilteritinib hemifumarate, 酪氨酸蛋白激酶受体 UFO 抑制剂

CAS: 1254053-84-3 货号: G646579 分子式: C29H44N8O3 0.5C4H4O4 分子量: 610.75 PubChem CID: 76970819
有货
级别和纯度: ≥99%
别名
吉特替尼半富马酸盐
储存条件
2-8°C储存
运输条件
低温运输
★
规格
库存
价格
数量
5mg
G646579-5mg
期货 Stock Image
¥1,000.90
10mg
G646579-10mg
期货 Stock Image
¥1,600.90
50mg
G646579-50mg
期货 Stock Image
¥5,600.90
100mg
G646579-100mg
期货 Stock Image
¥7,100.90
请输入您要添加的产品数量

概述


Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3 / AXL inhibitor with IC 50 of 0.29 nM/0.73 nM, respectively.

In Vitro

Of the 78 tyrosine kinases tested, Gilteritinib (ASP2215) inhibits FLT3, leukocyte tyrosine kinase (LTK), anaplastic lymphoma kinase (ALK), and AXL kinases by over 50% at 1 nM with an IC 50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT. Gilteritinib inhibits the activity of eight of the 78 tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and AXL) or 5 nM (TRKA, ROS, RET, and MER). The IC 50 s are 0.29 nM for FLT3 and 0.73 nM for AXL. Gilteritinib inhibits FLT3 at an IC 50 that is approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM). The antiproliferative activity of Gilteritinib is evaluated against MV4-11 and MOLM-13 cells, which endogenously express FLT3-ITD. After 5 days of treatment, Gilteritinib inhibits the growth of MV4-11 and MOLM-13 cells with mean IC 50 s of 0.92 nM (95% CI: 0.23-3.6 nM) and 2.9 nM (95% CI: 1.4-5.8 nM), respectively. Growth suppression of MV4-11 cells is accompanied by inhibition of FLT3 phosphorylation. Relative to vehicle control cells, phosphorylated FLT3 levels are 57%, 8%, and 1% after 2 h of treatment with 0.1 nM, 1 nM, and 10 nM Gilteritinib, respectively. In addition, doses as low as 0.1 nM or 1 nM result in the suppression of phosphorylated ERK, STAT5, and AKT, all of which are downstream targets of FLT3 activation. To investigate the effects of Gilteritinib on AXL inhibition, MV4-11 cells that expressed exogenous AXL are treated with Gilteritinib. At concentrations of 1 nM, 10 nM, and 100 nM for 4 h, Gilteritinib treatment decreases phosphorylated AXL levels by 38%, 29%, and 22%, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In MV4-11 xenografted-mice, the concentration of Gilteritinib (ASP2215) in tumors is more than 20-fold higher than that in plasma with oral administration of Gilteritinib at 10 mg/kg for 4 days. Treatment of Gilteritinib for 28 days results in dose-dependent inhibition of MV4-11 tumor growth and induces complete tumor regression at more than 6 mg/kg. Further, Gilteritinib decreases tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

The effect of Gilteritinib on MV4-11 and MOLM-13 cells is assessed using the CellTiter-Glo Luminescent Cell Viability Assay. Subsequent studies are conducted to examine the effect of Gilteritinib and Quizartinib on Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691 L, or FLT3-ITD-F691I. MV4-11 and MOLM-13 cells are treated with DMSO or increasing concentrations of Gilteritinib (0.01, 0.1, 1, 10, and 100 nM) for 5 days, and cell viability is measured using CellTiter-Glo. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:IC50: 0.29 nM (FLT3), IC50: 0.35 nM (LTK), 0.73 nM (AXL), 1.2 nM (EML4-ALK), 230 nM (c-KIT)

规格

别名
吉特替尼半富马酸盐
英文别名
Gilteritinib hemifumarate | GILTERITINIB FUMARATE [JAN] | ASP2215 hemifumarate | ASP-2215 hemifumarate | 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-butenedioate (2:1) | Xospata (TN) | Gilteritinib fumarate [USAN] | GILTERITINIB FUMARAT 展开
规格或纯度
≥99%
英文名称
Gilteritinib hemifumarate
生化机理
吉瑞替尼(ASP2215)半富马酸盐是一种强效的 ATP 竞争性 FLT3 / AXL 抑制剂,其 IC 50 分别为 0.29 nM/0.73 nM。
储存条件
2-8°C储存
运输条件
低温运输
作用类型
抑制剂
作用机制
酪氨酸蛋白激酶受体 UFO 抑制剂
纯度
≥99%
名称和识别符
分子类型
小分子
IUPAC Name
(E)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
InChI
1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+
InChIKey
UJOUWHLYTQFUCU-WXXKFALUSA-N
SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=CC(=O)O)C(=O)O
Isomeric SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=C/C(=O)O)\C(=O)O
关联CAS
PubChem CID
分子量
610.75

高级数据

系统学分类

分类树(Taxonomy Tree)

界(kingdom) 有机化合物
超类(Superclass) 有机杂环化合物
类(Class) 哌啶类
亚类(Subclass) 苯基哌啶
中间层级节点(Intermediate Tree Nodes) 暂无
直接上位类(Direct Parent) 苯基哌啶
其他上位类(Alternative Parents) 吡嗪酰胺类  氨基苯醚  甲氧基苯胺  茴香醚  苯氧基化合物  二烷基芳胺  2-杂芳基酰胺  甲氧基苯  氨基吡嗪类  氨基哌啶类  仲烷基芳胺  烷基芳基醚  N-甲基哌嗪  不饱和脂肪酸  氧烷  二羧酸及其衍生物  咪唑内酰胺类  乙烯基酰胺  杂芳族化合物  三烷基胺  氨基酸及其衍生物  伯羧酸酰胺  氧环化合物  二烷基醚  羧酸  氮杂环化合物  碳氢化合物衍生物  羰基化合物  有机氧化物  
分子骨架(Molecular Framework) 暂无
取代基(Substituents) 1,4-二氮杂环丁烷 - 2-异芳基甲酰胺 - 4-氨基哌啶 - 芳基醚 - 氨基酸 - 氨基酸或其衍生物 - 氨基苯醚 - 氨基吡嗪 - 苯胺或取代苯胺 - 茴香醚 - 芳香族杂单环化合物 - 氮杂环 - 苯基化合物 - 羰基 - 羧酰胺基 - 羧酰胺基 - 羧酸衍生物 - 二烷基醚 - 二烷基芳基胺 - 二羧酸或其衍生物 - 乙醚 - 脂肪酸 - 脂肪酰基 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 甲氧基苯胺 - 甲氧基苯 - 单环苯基基团 - N-烷基哌嗪 - N-甲基哌嗪 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂环丁烷 - 苯酚醚 - 苯氧基化合物 - 苯基哌啶 - 哌嗪 - 醛基胺 - 吡嗪 - 吡嗪羧酸或其衍生物 - 吡嗪甲酰胺 - 二级脂肪族/芳香族胺 - 醛基 - 三元脂肪胺 - 三芳基胺 - 不饱和脂肪酸 - 乙烯酰胺
描述(Description) 该化合物属于苯基哌啶类有机化合物。这类化合物具有苯基哌啶骨架,即哌啶与苯基相连的结构。
外部描述符(External Descriptors) 暂无
三维结构
交互式化学结构模型





化学和物理性质
溶解性
H2O : 2 mg/mL (3.27 mM; Need ultrasonic) Ethanol : 2 mg/mL (3.27 mM; ultrasonic and warming and adjust pH to 3 with 1M HCl and heat to 60°C) DMSO : 1.74 mg/mL (2.85 mM; Need ultrasonic and warming)
分子量
1221.500 g/mol
XLogP3
氢键供体数Hydrogen Bond Donor Count
8
氢键受体数Hydrogen Bond Acceptor Count
24
可旋转键计数Rotatable Bond Count
20
精确质量Exact Mass
1220.72 Da
单同位素质量Monoisotopic Mass
1220.72 Da
拓扑极表面积Topological Polar Surface Area
317.000 Ų
重原子数Heavy Atom Count
88
形式电荷Formal Charge
0
复杂度Complexity
904.000
同位素原子数Isotope Atom Count
0
定义的原子立体中心计数Defined Atom Stereocenter Count
0
未定义的原子立体中心计数Undefined Atom Stereocenter Count
0
定义的键立体中心计数Defined Bond Stereocenter Count
1
未定义的键立体中心计数Undefined Bond Stereocenter Count
0
所有立体化学键的总数The total count of all stereochemical bonds
1
共价键合单元计数Covalently-Bonded Unit Count
3
安全和危险性(GHS)
质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器

常见问题

本产品的纯度是多少?
本产品的化学纯度(含量)为 ≥99%。批次的具体数值以分析证书(COA)为准。
本产品应如何储存?
请于2–8 °C条件下保存。需冷藏保存以维持规定的有效期。
本产品如何运输?
本产品采用湿冰冷藏运输。收货后请立即拆包,并按上述储存条件保存。
本产品的 CAS 号、分子式和分子量是多少?
本产品的 CAS 号为 1254053-84-3,分子式为 C29H44N8O3 0.5C4H4O4,分子量为 610.75 g/mol。InChIKey UJOUWHLYTQFUCU-WXXKFALUSA-N。
如何获取批次专用COA?
每个订单都会随附分析证书(COA),您也可以从账户订单历史中下载。如需订购前的COA,请联系您的客户代表,或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。